Welcome to our dedicated page for Ispecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on Ispecimen stock.
iSpecimen Inc. (NASDAQ: ISPC) operates a global technology platform connecting life science researchers with healthcare providers to streamline biospecimen procurement. This page aggregates official company announcements, financial disclosures, and operational updates critical for understanding its role in advancing medical research.
Investors and stakeholders gain real-time access to press releases covering strategic partnerships, regulatory milestones, and marketplace expansions. Key updates include earnings reports, technology innovations like the Next Day Quote program, and collaborations enhancing global specimen availability.
Bookmark this page for timely insights into iSpecimen’s progress in addressing biospecimen sourcing challenges. Regular updates ensure you stay informed about developments impacting oncology research, infectious disease studies, and the company’s growing healthcare network.
iSpecimen (Nasdaq: ISPC) announced the expansion of its global biospecimen provider network to support research on neurological disorders, affecting approximately one billion people worldwide. Over the past ten months, it has added over a dozen sample providers, supplying biospecimens such as cerebrospinal fluid and other biofluids. iSpecimen can now provide samples from COVID-19 patients exhibiting neurological symptoms, assisting researchers facing biospecimen shortages. This initiative follows National Epilepsy and Alzheimer’s Awareness Months, aiming to facilitate medical discoveries related to these conditions.
iSpecimen Inc. (Nasdaq: ISPC) has successfully closed a private placement, raising approximately $21 million by selling 1,749,999 shares of common stock and warrants to purchase 1,312,500 shares. Each share was sold at a price of $12.00, accompanied by three-quarters of a warrant, which has an exercise price of $13.00 and a term of five and a half years. The private placement was managed by ThinkEquity. The securities offered will not be registered under the Securities Act, and iSpecimen plans to file a registration statement with the SEC for resale purposes.
iSpecimen (Nasdaq: ISPC) has announced a definitive agreement for a private placement to sell 1,749,999 shares of common stock and warrants, expecting to raise approximately $21.0 million in gross proceeds. Each share is priced at $12.00, accompanied by warrants exercisable at $13.00 per share. The placement is set to close on December 1, 2021, subject to customary conditions. The securities will not be registered under the Securities Act and will require a registration statement for resale. This transaction aims to strengthen the company's liquidity and financial position.
iSpecimen (Nasdaq: ISPC), a marketplace for human biospecimens, has secured contracts to support advanced COVID-19 research focusing on transmissibility and variant outcomes. The company has partnered with various research organizations over the past ten months, providing samples like nasal swabs and blood products. Notably, iSpecimen has supplied 600 positive and 100 negative serum samples to the CDC for antibody monitoring. Their work extends to military and private organizations, facilitating custom COVID-19 collections across diverse demographics to aid ongoing studies.
iSpecimen reported strong financial results for Q3 2021, with revenue increasing by 21% to $2.7 million, driven by expanding sales efforts and a growing user base. The company's nine-month revenue surpassed $8.6 million, a 57% increase compared to 2020. Notably, unique suppliers increased to 197 and registered users in the marketplace grew 30% year-over-year. Despite increasing general and administrative expenses to $1.7 million, the net loss reduced to approximately $1.1 million. iSpecimen aims to broaden its offerings and enhance its technology moving forward.
iSpecimen Inc. (Nasdaq: ISPC) announces participation in two virtual conferences in November 2021: A.G.P.'s Biotech & Specialty Pharma Conference on November 10 and the 12th Annual Craig-Hallum Alpha Select Conference on November 16. These events will provide opportunities for one-on-one meetings with management. iSpecimen specializes in connecting life scientists to human biospecimens through a unique online marketplace and cloud-based technology, enhancing medical discovery efforts. For more details, visit www.ispecimen.com.
iSpecimen Inc. (NASDAQ: ISPC) will announce its third quarter financial results on November 4, 2021, before market open. The conference call is scheduled for 8:30 a.m. ET, featuring remarks from CEO Christopher Ianelli, CFO Tracy Curley, and COO Jill Mullan. Interested individuals can join the call via toll-free numbers or access a replay until November 18, 2021. The company provides an online marketplace for human biospecimens, connecting scientists with healthcare providers for medical research.
iSpecimen Inc. (Nasdaq: ISPC) announced an expansion of its human biospecimen supplier network to enhance the availability of whole blood, plasma, and biofluids for liquid biopsy development. This move aims to support a growing market projected to reach $1.45 billion with a 24% annual growth rate through 2026. The company has supplied thousands of biospecimens for nearly 30 studies, reinforcing its commitment to advancing liquid biopsy technology, which offers less invasive disease detection methods.
iSpecimen Inc. (Nasdaq: ISPC) announced its inclusion in the Russell Microcap Index, effective September 20, 2021. This inclusion signifies recognition of the company's growth in the biospecimen procurement sector, expected to enhance visibility within the investment community. Being part of the Russell indexes, which benchmark approximately $10.6 trillion in assets, positions iSpecimen favorably for attracting institutional investors. The company is also refining its iSpecimen Marketplace, aiming to support researchers in scientific discovery.
iSpecimen (Nasdaq: ISPC), a leader in the online marketplace for human biospecimens, announced CEO Christopher Ianelli will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. His presentation will be available on-demand starting September 13 at 7:00 a.m. ET. iSpecimen connects life scientists with healthcare providers through its innovative platform to facilitate medical discovery.